Abstract：ObjectiveTo observe and analyze the clinical efficacy and adverse reactions of Pemetrexed combined with Tegafur Gimeracil Otera in the treatment of recurrent metastatic breast cancer.MethodsFrom August 2015 to August 2016,56 patients with recurrent metastatic breast cancer in our hospital were selected and randomly divided into the control group and the observation group,28 cases in each group.In the observation group,Pemetrexed combined with Tegafur Gimeracil Otera was adopted,every 3 weeks was considered as a treatment cycle.In the control group,only Tegafur Gimeracil Otera was used,every participant should be treated for at least two cycles,and effect and adverse reactions were evaluated between the two groups.ResultsIn the observation group,the survival rate and recurrence rate were 75.00%and 3.57%respectively,which were both superior to those in the control group(35.71%,39.29%),with significant difference(P＜0.05).There was no significant difference between the two groups in mortality(P＞0.05).The incidence of digestive tract reaction in the observation group was 32.14%,the incidence rate of hematologic toxicity was 46.43%,and the incidence of liver function toxicity was 32.14%,which were lower than those in the control group(57.14%,72.43%,25.00%),with significant difference (P＜0.05).There was no significant difference in the incidence of neurotoxicity and liver function toxic reaction between the two groups(P＞0.05).ConclusionCombination of Pemetrexed and Tegafur Gimeracil Otera can obtain a remarkable effect on treating recurrent metastatic breast cancer in a low adverse reactions.It can be tolerated and is worthy of clinical promotion and research.
王敏 ；赵建华. 培美曲塞联合替吉奥治疗复发转移性乳腺癌的临床效果[J]. 中国当代医药, 2017, 24(29): 53-55.
WANG Min ；ZHAO Jian-hua. Clinical effect of Pemetrexed combined with Tegafur Gimeracil Otera in the treatment of recurrent metastatic breast cancer. 中国当代医药, 2017, 24(29): 53-55.
京公网安备 11010502046607号